Last reviewed · How we verify
NCT03901391: RU-RP
Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa
trial testing Whole Exome Sequencing in Retinitis Pigmentosa in 130 participants. Completed in 20 October 2020.
19 October 2020
Quick facts
| Lead sponsor | Sensor Technology for Deafblind |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 130 |
| Start date | 26 March 2019 |
| Primary completion | 19 October 2020 |
| Estimated completion | 20 October 2020 |
| Sites | 2 locations across Russia |
Drugs / interventions tested
- Whole Exome Sequencing
Conditions studied
- Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
- Usher Syndromes — all drugs for Usher Syndromes →
Sponsor
Sensor Technology for Deafblind
Who can join
Adults 6 to 65, any sex, with Retinitis Pigmentosa or Usher Syndromes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aimed to characterize Russian population of Retinitis Pigmentosa
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: e-Posters.
· 2020 · cited 4× · PMID 33262486 · DOI 10.1038/s41431-020-00741-5
Verify or expand the search:
- PubMed search for NCT03901391
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Whole Exome Sequencing
Trials testing the same drug.
- NCT04384250 — Genetic and Immunologic Basis of COVID-19 Infection · completed
- NCT04126915 — Precise Therapy for mCRPC Patients Through Whole Exome Sequencing(PTtWES) · unknown
- NCT03911531 — Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops · recruiting
- NCT03427593 — Severe PID With Lymphoproliferation and Neutropenia · NA · completed
- NCT03525431 — Clinical Utility of Pediatric Whole Exome Sequencing · NA · completed
Other recruiting trials for Retinitis Pigmentosa
Currently open trials in the same condition.
- NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
- NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting
Other Sensor Technology for Deafblind trials
Trials by the same sponsor.
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT03319524 — Clinical and Genetic Testing of Patients With Usher Syndrome · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03901391 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sensor Technology for Deafblind
- Last refreshed: 20 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03901391.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing